Research summary, original research, 2016

Impact of New-generation Hybrid Imaging Technology on Radiation Dose during Percutaneous Coronary Interventions and Trans-femoral Aortic Valve Implantations: A comparison with conventional flat-plate angiography

Boland JE, Wang LW, Love BJ, Christofi M, Muller DW. Heart, lung & circulation. 2016

Read the original paper

In plain language

In 140 percutaneous coronary intervention (PCI) and transcatheter aortic valve implantation (TAVI) procedures, a newer hybrid imaging system was associated with 26% lower patient dose-area product for PCI, with no significant change for TAVI. Staff dose was not measured directly.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients
Size
n = 140 procedures
Summary based on
the abstract

What it found

  • After adjustment for patient weight and fluoroscopy time, dose-area product (DAP) for single-vessel PCI was 26% lower with the Siemens Artis Zeego hybrid system than with the Philips FD20.

    Key figures: 55.6 (27.0-91.5) vs 77.6 (51.2-129.1) Gy.cm(2), P=0.03

  • Tomographic imaging with the Zeego did not significantly increase DAP for TAVI compared with the FD20.

    Key figures: 98.1 (65.9-136.6) vs 112.4 (64.9-156.2) Gy.cm(2), P=NS

  • Fluoroscopy times were longer for TAVI than PCI on both systems.

    Key figures: 23.5-24.4 vs 7.3-9.2mins, p<0.0001

  • The dose-reducing features reduced DAP more for PCI than for TAVI, attributed to additional cine acquisition needed for valve procedures.

Limits to keep in mind

Observational single-comparison study with small samples and different time periods per system; only patient dose-area product was measured, not staff dose.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.